Literature DB >> 21217178

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Catherine Liu1, Arnold Bayer, Sara E Cosgrove, Robert S Daum, Scott K Fridkin, Rachel J Gorwitz, Sheldon L Kaplan, Adolf W Karchmer, Donald P Levine, Barbara E Murray, Michael J Rybak, David A Talan, Henry F Chambers.   

Abstract

Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217178     DOI: 10.1093/cid/cir034

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  451 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

2.  Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jose Cadena; Shalini Nair; Andres F Henao-Martinez; James H Jorgensen; Jan E Patterson; Pranavi V Sreeramoju
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

3.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

Review 4.  Postoperative infections of the lumbar spine: presentation and management.

Authors:  Dennis S Meredith; Christopher K Kepler; Russel C Huang; Barry D Brause; Oheneba Boachie-Adjei
Journal:  Int Orthop       Date:  2011-12-10       Impact factor: 3.075

5.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

6.  Severe MRSA necrotizing pneumonia.

Authors:  S Rasul; F Farhat; S A Asnake
Journal:  Infection       Date:  2012-05-25       Impact factor: 3.553

Review 7.  Current trends in the management of cardiac implantable electronic device (CIED) infections.

Authors:  Emanuele Durante-Mangoni; Irene Mattucci; Federica Agrusta; Marie-Françoise Tripodi; Riccardo Utili
Journal:  Intern Emerg Med       Date:  2012-06-29       Impact factor: 3.397

Review 8.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

9.  Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Authors:  Amanda Gwee; Noel Cranswick
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

10.  Artificial Selection for Pathogenicity Mutations in Staphylococcus aureus Identifies Novel Factors Relevant to Chronic Infection.

Authors:  Kathryn McLean; Elizabeth A Holmes; Kelsi Penewit; Duankun K Lee; Samantha R Hardy; Mingxin Ren; Maxwell P Krist; Kevin Huang; Adam Waalkes; Stephen J Salipante
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.